NDAORALSOLUTION
Approved
Jun 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PRIMSOL is an oral trimethoprim hydrochloride solution approved in 1995 for treating bacterial urinary tract infections. It is a dihydrofolate reductase inhibitor that disrupts bacterial DNA synthesis by blocking folate metabolism. The drug is indicated for uncomplicated urinary tract infections in adults.
LOE Approaching
With LOE approaching and moderate competitive pressure (30%), the commercial team is likely focused on maximizing remaining branded market share through key account and institutional relationships rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Roles on PRIMSOL focus exclusively on commercial account management and institutional relationships, reflecting a mature product in LOE stage. Working on this product develops deep expertise in contracting, managed care navigation, and relationship-based selling in a competitive, price-sensitive market segment.
Key Account ManagerInstitutional Account Manager
Worked on PRIMSOL at TerSera Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.